ArticleSignal transduction and targeted therapy2020
An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma.
Article in Signal transduction and targeted therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- Targeting mir130b-IL-33-PD-L1 axis effectively inhibits esophageal squamous carcinoma progression.Translational oncology · 2026Article
- Development and validation of a biopsy-based model using tumor-associated neutrophils to predict neoadjuvant chemotherapy response in osteosarcoma: a large single-center retrospective cohort study.Journal of bone oncology · 2026Article
- Radiation dose escalation in locally advanced oesophageal cancer: a systematic review and hierarchical Bayesian meta-analysis.EClinicalMedicine · 2025Article
- TP53-centric ctDNA complements PET/CT for non-invasive assessment of pathological complete response and survival after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a prospective cohort study.International journal of surgery (London, England) · 2025Observational
- Prognostic analysis of esophageal cancer patients after neoadjuvant therapy.Frontiers in immunology · 2025Article
- Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.Cancer medicine · 2024Article
- Clinical significance, molecular characterization, and immune microenvironment analysis of coagulation-related genes in clear cell renal cell carcinoma.Cancer innovation · 2024Article
- Laboratory blood parameters and machine learning for the prognosis of esophageal squamous cell carcinoma.Frontiers in oncology · 2024Article
- Molecular phenotypic linkage between NJournal of cancer research and clinical oncology · 2023Article
- Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction.Biomarker research · 2023Review
- Article
- Article
- The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing.Signal transduction and targeted therapy · 2022Article
- Necroptosis-Related LncRNAs Signature and Subtypes for Predicting Prognosis and Revealing the Immune Microenvironment in Breast Cancer.Frontiers in oncology · 2022Article
- Comprehensive analysis of the importance of PLAUR in the progression and immune microenvironment of renal clear cell carcinoma.PloS one · 2022Article
- The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer-A Review.Frontiers in oncology · 2022Review
- RNA NClinical and translational medicine · 2021Review
- Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs.Signal transduction and targeted therapy · 2021Article
- Tumor-infiltrating CD8Clinical and translational medicine · 2021Article
- Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No clinically available biomarkers can predict pathological complete response (pCR) for esophageal squamous cell carcinomas (ESCCs) with neoadjuvant chemoradiotherapy (nCRT). Considering that antitumor immunity status is an important determinant for nCRT, we performed an integrative analysis of immune-related gene profiles from pretreatment biopsies and constructed the first individualized immune signature for pCR and outcome prediction of ESCCs through a multicenter analysis. During the discovery phase, 14 differentially expressed immune-related genes (DEIGs) with greater than a twofold change between pCRs and less than pCRs (<pCRs) were revealed from 28 pretreatment tumors in a Guangzhou cohort using microarray data. Ten DEIGs were verified by qPCR from 30 cases in a Beijing discovery cohort. Then, a four-gene-based immune signature (SERPINE1, MMP12, PLAUR, and EPS8) was built based on the verified DEIGs from 71 cases in a Beijing training cohort, and achieved a high accuracy with an area under the receiver operating characteristic curve (AUC) of 0.970. The signature was further validated in an internal validation cohort and an integrated external cohort (Zhengzhou and Anyang cohorts) with AUCs of 0.890 and 0.859, respectively. Importantly, a multivariate analysis showed that the signature was the only independent predictor for pCR. In addition, patients with high predictive scores showed significantly longer overall and relapse-free survival across multiple centers (P < 0.05). This is the first, validated, and clinically applicable individualized immune signature of pCR and outcome prediction for ESCCs with nCRT. Further prospective validation may facilitate the combination of nCRT and immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.